MedTrace Logo

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

NCT02077868 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2019-09-10

No results posted yet for this study

Summary

The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.

Conditions

Interventions

OTHER

Usual Maintenance

Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other

DRUG

MGN1703 treatment

MGN1703 will be used as single agent maintenance treatment

Sponsors & Collaborators

  • Mologen AG

    lead INDUSTRY

Principal Investigators

  • David Cunningham, MD · Royal Marsden Hospital London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-02-28
Completion
2020-05-31

Countries

  • Austria
  • Belgium
  • Estonia
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077868 on ClinicalTrials.gov